Fri.Oct 18, 2024

article thumbnail

STAT+: Chickenpox, shingles, Alzheimer’s? Evidence mounts for a viral cause of dementia

STAT

Pascal Geldsetzer believes in open access, in disseminating science as quickly as it happens. Even so, last summer, as he uploaded the surprising results of his latest study to the MedRxiv preprint server, the Stanford University epidemiologist was feeling something other than the usual excitement. “I was scared to put this up because it’s such a different approach from what’s generally done in epidemiology and medicine,” he said.

363
363
article thumbnail

Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with

PharmaVoice

From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.

162
162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

D.A. Wallach on his wife’s tragic death and creating a ‘golden record’ for medicine

STAT

D.A. Wallach met his late wife, Liz, at a Halloween party in Los Angeles hosted by the Maroon 5 star Adam Levine.  At the time, the erstwhile indie rocker never imagined that his relationship, and his career, would lead him to declare an all-out war on the U.S. health system. But then, Wallach said Thursday, she died four years ago, the day after giving birth.

Hospitals 352
article thumbnail

Women in more deprived areas half as likely to access HRT, data shows

The Pharmacist

Women in deprived areas are accessing hormone replacement therapy (HRT) on the NHS at nearly half the rate of women in more affluent areas, the latest data shows. According to analysis by The Pharmacist, just 10% of women aged 45-59 living in the 20% most deprived areas in England were given HRT on the NHS in […] The post Women in more deprived areas half as likely to access HRT, data shows appeared first on The Pharmacist.

140
140
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

STAT+: Sales from controversial drug discount program rose to $63 billion last year

STAT

Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $63 billion in 2023, a 23.4% increase from the previous year, according to the Health Resources & Services Administration, which oversees the program. The data mark a steady rise in sales under the 340B Drug Discount Program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — off all outpatient drugs to hospit

Hospitals 317

More Trending

article thumbnail

One doctor’s quest to help people with hearing loss enjoy ‘all the richness’ of music

STAT

As a child in Jacksonville, Fla., Alex Chern built string instruments out of office supplies and tuned them, stretching rubber bands taut to change their pitch. Starting at age 7, he took violin lessons and continued playing all the way through college at Yale University. He loved playing Beethoven, expressive pieces written in F major like “Romance No. 2” or the “Spring Sonata,” and technically challenging pieces like Bach’s “Sonatas and Partitas,ȁ

article thumbnail

BenevolentAI CEO steps down as founders make a comeback

pharmaphorum

Jörg Möller's sojourn as CEO of BenevolentAI has come to an abrupt end, as the firm names co-founder Ken Mulvany as executive chair

116
116
article thumbnail

STAT+: How a drug discount program intended to benefit the poor got entangled in a California rent-control fight

STAT

WASHINGTON — Californians are about to vote on an aggressive policy proposals to reform a drug discount program that is a key source of revenue for hospitals and health clinics. The group behind it? Apartment builders.  As a general rule, programs named after the sub-section of the law in which they were created are not well-known. The 340B Drug Discount Program is no exception.

article thumbnail

AbbVie gets continuous Parkinson's drug over the line in US

pharmaphorum

AbbVie has finally claimed FDA approval for its 24-hour Parkinson's therapy Vyalev, 18 months after the US regulator turned it down

115
115
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Potential competition for RSV prophylactic Beyfortus

STAT

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Good morning! For those who were wise enough to attend, hope you enjoyed this year’s STAT Summit. Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more.

article thumbnail

MSD preparing to take on Beyfortus with RSV antibody

pharmaphorum

MSD reveals the data that could unlock filings for clesrovimab, a rival to Sanofi and AstraZeneca's Beyfortus for preventing infant RSV infections

115
115
article thumbnail

Morning Rounds: A STAT crossword, Atul Gawande, and hearing music with hearing aids

STAT

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. I’m recovering from the STAT Summit — in particular, recovering from this stunning view of Boston from the venue. On Wednesday evening, we had an amazing view of the almost-supermoon rising as dusk settled in during the last panel of the day.

270
270
article thumbnail

mRNA licensing agreements surge 800% amid GSK lawsuits

Pharmaceutical Technology

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are facing lawsuits.

Vaccines 111
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

STAT+: CVS Health replaces CEO as it faces a range of challenges

STAT

CVS Health has replaced Karen Lynch with David Joyner as CEO, it said Friday, part of an attempt to turn the struggling company around.  Joyner was previously the president of CVS Caremark, the company’s pharmacy benefit manager, and formerly worked at Aetna, the insurer now owned by CVS. The company said Lynch had stepped down “in agreement” with the company’s board.

270
270
article thumbnail

Opioid addiction market to reach $2.4 billion across 8MM by 2033

Pharmaceutical Technology

Late-stage pipeline products could drive combined sales of approximately $171.4 million by 2033 in the 8MM.

107
107
article thumbnail

Opinion: STAT+: Genentech executive Fritz Bittenbender: Beware political soundbites

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You can also read Eli Lilly chief scientist Daniel M. Skovronsky on fallacies surrounding patents, drug discovery, and affordability,   Sandoz CEO Richard Saynor  on what the 2024 conversation is missin

article thumbnail

Merck antibody reduces RSV-related disease, hospitalizations in trial

BioPharma Dive

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Hospitals 107
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

215
215
article thumbnail

2024 PharmaVoice 100s: Cardiometabolic All-Stars

PharmaVoice

Leaders tackling long-standing health needs with new solutions.

100
100
article thumbnail

STAT+: Amgen, Biogen and Takeda talk about R&D on tough targets

STAT

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their insights on their differing challenges in a hot space for obesity drugs, an industry that doesn’t favor midsize companies, and a disappointing market for Alzheimer’s treatments — so far.

213
213
article thumbnail

Frontiers Health 2024: Day Two

pharmaphorum

Frontiers Health 2024: Day Two Mike.

98
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Intercept’s liver disease drug Ocaliva faces FDA approval delay

Pharmaceutical Technology

An FDA AdCom in September recommended against full approval for Ocaliva by a 13-1 vote for the treatment of primary biliary cholangitis.

98
article thumbnail

EMA Denies Authorization of Duchenne Muscular Dystrophy Treatment, Again

PharmaTech

The agency has reconfirmed its recommendation to not give positive opinion to Translarna (ataluren) after a reexamination of the available data.

98
article thumbnail

Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study

World Pharma News

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo® (faricimab) for the treatment of diabetic macular edema (DME) in people from racial and ethnic groups that are often underrepresented in clinical trials.(4) The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as

article thumbnail

Weight loss jabs not ‘quick fix’ for worklessness, health experts warn

The Guardian - Pharmaceutical Industry

Scientists say using the drugs to get people back into work could carry logistical and ethical problems Weight loss jabs are not a “quick fix” and the health secretary’s plan to use them to help people get back to work could backfire, experts have warned. Wes Streeting announced a real-world trial of the medication’s impact on worklessness this week, saying that “widening waistbands” were placing a burden on the NHS.

86
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.